| From: Candu | 3/7/2022 9:16:03 AM | | | | | | |
Guelph, ON
March 7, 2022
Zentek Ltd. (“ZEN” or the “Company”) TSX-V:ZEN and OTC:ZENYF), a Canadian IP development and commercialization company focused on next-gen healthcare solutions, today announces that it has received approval to have its common stock listed on the Nasdaq Capital Market (“Nasdaq”) under the symbol ZTEK. Zentek’s common stock will continue to trade on the TSX Venture Exchange (TSX-V) under the symbol ZEN. The Company is evaluating market conditions and other considerations and will announce the date its shares will commence trading in due course but no later than the 60-day limit as of March 4th.
Greg Fenton, CEO of Zentek, commented, “We believe the move to Nasdaq will be pivotal in generating additional interest and awareness in the U.S. investment community and is reflective of our transition to a global technology company focused on disruptive intellectual property in the areas of healthcare and sustainability. We anticipate this listing will improve the visibility of our stock, enhance trading liquidity in our shares, and provide us with greater exposure to institutional investors.”
About Zentek Ltd.
Zentek is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection and treatment. Zentek is commercializing ZenGUARD™, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases. The Company also has an exclusive agreement to be the global exclusive commercializing partner for a newly developed, highly scalable, aptamer-based rapid pathogen detection technology.
For further information:
Matt Blazei
Tel: (212) 655-0924
Email: mattb@coreir.com
To find out more about Zentek Ltd., please visit our website at www.Zentek.com. A copy of this news release and all material documents in respect of the Company may be obtained on ZEN’s SEDAR profile at www.sedar.com.
Forward-Looking Statements
This news release contains forward-looking statements. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although Zentek believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zentek disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
|
|
|
|
| | Zentek Ltd - ZEN | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| From: Inca2 | 3/8/2022 9:18:21 AM | | | | | | Guelph, ON
March 8, 2022, Zentek Ltd. (“ZEN” or the “Company”) (TSX-V:ZEN and OTC:ZENYF), a Canadian IP development and commercialization company focused on next-gen healthcare solutions, today announces the addition of Mr. Ravi Kaza to its Advisory Board.
Mr. Kaza graduated from The Wharton School of the University of Pennsylvania with a BS in Finance Summa Cum Laude at age 19 and has spent the last 25 years consistently focused on disruptive technologies. He started his career in Silicon Valley at a prominent investment banking group founded by Frank Quattrone where he worked on numerous transactions involving companies such as Amazon, Apple, Northern Telcom, and Lam Research. Mr. Kaza then entered the money management business as a Vice President at Pequot Capital Management, at the time one of the world’s largest alternative asset managers with a focus on technology investing. He was then hired by Stanley Druckenmiller as a Managing Director at Duquesne Capital Management to focus primarily on technology investing.
In 2003, Mr. Kaza founded Seasons Capital Management, which he helped grow into a multi-billion-dollar alternative investment manager that oversaw several technology-related investment strategies. In 2010, Mr. Kaza shifted his focus to running primarily internal capital with a continued primary focus on disruptive technologies. Consistent with this focus, Mr. Kaza was introduced to the Zentek management team during the Summer of 2021, when he became a shareholder.
“We are thrilled to have Mr. Ravi Kaza join our Advisory Board,” Greg Fenton, CEO of Zentek commented. “Ravi has a remarkable track record working with and investing in companies with highly disruptive and scalable technologies. His experience and guidance will be extremely valuable to Zentek moving forward.” |
| | Zentek Ltd - ZEN | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: Inca2 | 3/10/2022 9:13:36 AM | | | | | | Guelph, ON
March 10, 2022
Zentek Ltd. (“ZEN” or the “Company”) (TSX-V: ZEN and OTC: ZENYF), a Canadian IP (Intellectual Property) development and commercialization company focused on next-gen healthcare solutions, today announces that it has retained Vimta Labs Limited (“Vimta”), a leading clinical research organization in India, to begin studies of ZEN’s ZenGUARD™ active ingredient as a potential treatment of infectious skin disease.
Vimta will be performing pre-clinical research on ZEN’s novel graphene oxide-silver active ingredient including collecting the in vitro and in vivo data that is required for the submission of an Investigational New Drug to the United States Food and Drug Administration (FDA) which is a requirement for the administration of a new drug in humans.
The pre-clinical program includes the following research:
- The permeation of the graphene oxide-silver active ingredient in three different formulations to select a formulation that will be used for the remaining studies;
- Analytical and bioanalytical studies to calibrate the detection of the active ingredient in biological samples;
- Acute studies of high dosages of the active ingredient for dermal application;
- Genetic toxicity studies; and
- Safety pharmacology studies and general toxicity studies.
The pre-clinical work with Vimta will begin immediately and is scheduled to be completed by Q4 2022.
The Company decided to move forward with this work following cytotoxicity studies with Nucro-Technics and positive anecdotal results of various human skin infections including acne, warts and toenail fungal infections. There were no adverse effects recorded during these anecdotal trials.
These human anecdotal cases form part of ZEN’s patent application filed December 21, 2021, under the Patent Cooperation Treaty entitled “Graphene-Silver Nanocomposites and Uses For Same As a Broad-Spectrum Antimicrobial” which is scheduled to be published on June 22, 2022.
Dr. Kenneth Reed, Dermatologist commented: "Although anecdotal observations are encouraging, the rigorous scientific analysis performed by Vimta will ensure the safety, formulation, and fortify the basic required data needed for FDA review, prior to the potential launch of a new therapeutic agent. The broad-spectrum antimicrobial effects of ZenGUARD™ make it particularly attractive as a topical formulation for the treatment of cutaneous disease with an infectious etiology.”
"This is another excellent example of the application opportunities for our broad-spectrum, patent-pending ZenGUARD™ technology," said Dr. Francis Dubé, Executive Chair at Zentek Ltd. "Consistent with our mission to develop innovative nanotechnologies with our partners, Vimta’s commitment to high-quality standards and building sustainable relationships will help Zentek to continue creating solutions that improve people’s lives."
About Zentek Ltd.
Zentek is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection and treatment. Zentek is currently focused on commercializing ZenGUARD™, a patent-pending coating shown to have 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as products against infectious diseases. The Company also has an exclusive agreement to be the global exclusive commercializing partner for a newly developed aptamer-based rapid pathogen detection technology.
For further information:
Matt Blazei
Tel: (212) 655-0924
Email: mattb@coreir.com
To find out more about Zentek Ltd., please visit our website at www.Zentek.com. A copy of this news release and all material documents in respect of the Company may be obtained on ZEN’s SEDAR profile at zentek.us20.list-manage.com.
Forward-Looking Statements
This news release contains forward-looking statements. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although Zentek believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zentek disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
|
|
| | Zentek Ltd - ZEN | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: Inca2 who wrote (13888) | 3/11/2022 2:38:58 AM | | From: Bentonstocks | | | | | The company is presumably taking every effort to steer us out of this short attack, but the only news that is really going to put a dent in in the short position and pull the share price higher is positive news on the saliva testers and the HVAC products approved and going to market. These are supposed to be our next-to-market major revenue generators, and we desperately need them... Everything else, particularly if it is just about research and testing of new products, is effectively just fluff that is not going to do anything for us in the near term. |
| | Zentek Ltd - ZEN | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: Bentonstocks | 3/11/2022 2:46:06 AM | | | | | | | Looking at the Zentek's "Our Team" webpage, it could maybe start to benefit from some racial diversity in my opinion, particularly as the company looks southward to expand its business and with requisite regulatory approvals. |
| | Zentek Ltd - ZEN | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: Bentonstocks | 3/12/2022 6:01:11 AM | | | | | | I have to say, after reading the various reports, I am beginning to question the wisdom of taking PP money from 8 Capital given the well established connection to Anson Funds. What's happening to our share price seems to follow the well-established playbook/modus operandi of AF and cohorts described in the various reports we have all recently read, which presumably many professionals would have already been well aware of at the time of our last PP.
There is a belief that the shorts have probably lost millions on their ZEN short, but I'm not sure I see that given that the share price has done nothing but decline since the PP was announced, and since 7 dollars. From my limited understanding and knowledge, it seems to me if, through 8 Capital, a shorter such as AF was participant in the PP and covered some of their short at the PP price, which was higher than when they initiated their short, then yes they would have lost. On the other hand, if they were not in any way participant in the PP, given that the share price has done nothing but decline since the PP was announced, then how have they lost anything yet if their short positions have been initiated at prices higher than the current SP? Or if they conspired to push the share price up to +7 dollars to then initiate their short positions, they still made money if they covered their short in the PP... It is also interesting to me that there has not really been any defense of the SP at the PP level, so what does that tell you about who participated in the PP, and what their objectives were?
On the other hand we have a big chunk of their money in the bank and and many positive developments in the pipeline, with a real product already to market - I wear one everyday. So maybe the thinking was, share price be damned in the short-term, take their money and then power-on with bringing our various products to market - short-term pain for long-term gain. If so, then maybe the apparent deal with Devil was worth it, but you have to think it was risky nonetheless given the reputations of AF and co and the damage they can cause... But maybe we were damned either way and it was least better to get some money in the process.
In any case, what we urgently need is to get some great news on the saliva testers and HVAC and get trading on the NAS, and certainly off the TSX-V, ASAP. That could turn things around quickly and maybe cause a big short-squeeze in the process, which would hopefully scare-off the shorts for good... I really hope the company has something akin to this strategy in the works, but it is also true that current global situation could take the shine off any great news we put out.
If anyone feels the need to correct my understanding of things, please feel free. |
| | Zentek Ltd - ZEN | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (6) |
|
| |
